CHDI Foundation selects Greenphire technology for global clinical payment
CHDI Foundation, a non-profit biomedical research organization focused on Huntington’s disease (HD), will be implementing Philadelphia-based Greenphire’s two flagship payment technology platforms, eClinicalGPS and ClinCard System, to enhance its payment capability in the upcoming Enroll-HD global observational study.
CHDI will be utilizing the eClinicalGPS platform to automatically calculate and deliver site and investigator payments in local currency across 29 countries. Greenphire's ClinCard System will also be implemented in order to deliver real-time electronic travel expense payments to study participants in local currency. The new relationship with CHDI expands on the rapid global adoption of the eClinicalGPS platform and the ClinCard System’s established record of success with pharmaceutical, biotechnology, medical device and CRO clients.
“We are delighted to work with Greenphire to ensure our payments worldwide are made more quickly, more simply and more securely so that our study teams can focus their energy on our patients, our sites and the clinical success of our studies,” said CHDI president Robi Blumenstein.
A joint analysis by Greenphire and CHDI estimated that integrating Greenphire’s technology platforms will considerably reduce costs associated with managing and delivering site and participant payments when compared to manual processes. Given Enroll-HD’s international profile, CHDI was particularly concerned that managing local compliance and foreign exchange complications across dozens of countries would incur significant cost and risk.
“As a global study, Enroll-HD needs a set of technologies that can benefit all our sites around the world,” said Joseph Giuliano, director of clinical operations, CHDI. “Throughout our planning stages the Greenphire team has shown they are capable of delivering efficient payment solutions that meet our needs.”
Enroll-HD is a longitudinal clinical observational study for HD patients that represents a continuation of CHDI’s ongoing REGISTRY and COHORT HD clinical studies. Enroll-HD will include over 230 sites across 29 countries.